Prognostic Factors and Management in Chronic Lymphocytic Leukemia in Young Patients: A Case Report
Main Article Content
Abstract
Chronic lymphocytic leukemia is the most common form of leukemia found in the West, primarily affecting individuals between 65 and 72 years old, with a survival rate of approximately 10 years. The aim of this study was to describe the clinical presentation of chronic lymphocytic leukemia by relating it to a case of a young patient wiyh this disease, seeking to discuss possible clinical factors associated with prognosis. To this end, a review of the patient's medical record was conducted, along with a search of the scientific literature, and articles presenting relevant data were selected for this study. Based on the research conducted, the importance of using the Chronic Lymphocytic Leukemia International Prognostic Index, which considers disease progression and aids in therapy, was noted. Additionally, it was observed that chronic lymphocytic leukemia is a disease that can significantly affect the life expectancy of affected individuals, especially older ones. However, despite the patient being young, her prognosis tends to be unfavorable, mainly due to the presence of unmutated immunoglobulin heavy chain variable region gene, which is associated with a poorer response to treatment and lower overall survival.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Baliakas P, Mattsson M, Stamatopoulos K, et al. Prognostic indices in chronic lymphocytic leukemia: where do we stand and where do we go? J Clin Med. 2020;9(2):627. doi:10.3390/jcm9020627.
3. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174. doi:10.1016/S0140-6736(10)61381-5.
4. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374 (4):311-322. doi:10.1056/NEJMoa1513257.
5. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet. 2008;371(9617):1017-1029. doi:10.1016/S0140-6736(08)60428-3.
6. Oscier D, Dearden C, Eren E, et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol. 2012;159(5):541-564. doi:10.1111/bjh.12067.
7. Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208-215. doi:10.1182/blood-2015-06-651125.
8. Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23-33.
doi:10.1016/j.annonc.2020.09.019.
9. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:481-488. doi:10.1182/asheducation-2010.1.481.
10. Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019;94(11):1266-1287. doi:10.1002/ajh.25678.
11. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42. doi:10.1056/NEJMoa1215637.
12. O'Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia: an open-label, multicentre, phase 1b-2 trial. Lancet Oncol. 2014;15(1):48-58. doi:10.1016/S1470-2045(13)70513-8.
13. Jain N, Thompson PA, Keating M. Initial treatment of CLL: integrating biology and functional status. Blood. 2018;131(23):2555-2564. doi:10.1182/blood-2017-12-784991.
14. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373 (25):2425-2437. doi:10.1056/NEJMoa1507226.
15. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3): 213-223. doi:10.1056/NEJMoa1400376.
16. International CLL-IPI Working Group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779-790. doi:10.1016/S1470-2045(16) 30029-8.
17. Wierda WG, O’Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109(11):4679-4685. doi:10.1182/blood-2006-09-043950.
18. Thompson PA, O'Brien SM. Higher-risk chronic lymphocytic leukemia: risk stratification and management. Hematology Am Soc Hematol Educ Program. 2019;2019(1):313-322. doi:10.1182/hematology.2019000039.
19. Roberts AW, Ma S, Kipps TJ, et al. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response characteristics. Blood. 2019;134(2):111-122. doi:10.1182/blood.2019001025.
20. Davids MS, Hallek M. Novel cellular therapies and their evolving role in CLL. Hematology Am Soc Hematol Educ Program. 2019;2019(1):136-143. doi:10.1182/hematology.2019000059.
21. Mato AR, Thompson MC, Allan JN, et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Blood Adv. 2020;4(4): 631-644. doi:10.1182/bloodadvances.2019001016.
22. Ghia P, Pluta A, Wach M, et al. Ascend: phase 3, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed/refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2849-2861. doi:10.1200/JCO.20.00588.